Ask AI
Barriers to CAR T Cell Therapy

CE / CME

From Evidence to Practice—Barriers to Access and Manufacturing Delays in CAR T-Cell Therapy

ABIM MOC: maximum of 0.50 Medical Knowledge MOC point

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

Released: December 09, 2025

Expiration: June 08, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

A 63-year-old woman with relapsed/refractory (R/R) multiple myeloma (MM) is referred for CAR T-cell therapy. Her T-cells have been successfully collected, and she is now awaiting manufacturing and infusion. She has a high disease burden but remains asymptomatic.

Which of the following best describes the rationale for using bridging therapy in this patient?